← All trials
NCT07260812
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 7, 2025
- Primary completion
- Jun 30, 2028
- Completion date
- Dec 31, 2028
- First posted
- Dec 3, 2025
- Last posted
- Dec 3, 2025
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- TScan Therapeutics, Inc.Lead sponsor
- Huazhong University of Science and TechnologyCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.